Vicadrostat clinical trials
Also written BI 690517.
How each study uses vicadrostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vicadrostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test vicadrostat, phase 3 first.
- Dec 2026EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Phase 3 · Boehringer Ingelheim
- Dec 2026A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyPhase 1 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses vicadrostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartRecruitingPhase 3Boehringer IngelheimNCT06935370Written as vicadrostat
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureRecruitingPhase 3Boehringer IngelheimNCT06424288Written as vicadrostat
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseRecruitingPhase 3Boehringer IngelheimNCT07064473Written as Vicadrostat
- A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyRecruitingPhase 1Boehringer IngelheimNCT07845630Written as Vicadrostat
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Active, not recruitingPhase 3Boehringer IngelheimNCT06531824Written as BI 690517
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseCompletedPhase 2Boehringer IngelheimNCT06926660Written as Vicadrostat
- A Study in Healthy People to Test How Vicadrostat Affects the HeartCompletedPhase 1Boehringer IngelheimNCT07513207Written as Vicadrostat
- A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and TogetherCompletedPhase 1Boehringer IngelheimNCT07035457Written as Vicadrostat
- A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are ToleratedCompletedPhase 1Boehringer IngelheimNCT03608072Written as BI 690517
- A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney DiseaseCompletedPhase 2Boehringer IngelheimNCT05182840Written as BI 690517
- This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are ToleratedCompletedPhase 1Boehringer IngelheimNCT03165240Written as BI 690517
- Single Rising Dose Study of BI 690517 in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02891148Written as BI 690517
- A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT05731908Written as BI 690517
- This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is ToleratedCompletedPhase 1Boehringer IngelheimNCT03206632Written as BI 690517
- A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the BodyCompletedPhase 1Boehringer IngelheimNCT05515588Written as BI 690517 (C-14)
Given beside what is tested · 2 — vicadrostat is usual care or a partner of the new treatment
- A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the BloodCompletedPhase 1Boehringer IngelheimNCT06647810Written as BI 690517 formulation 1
- This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the BloodCompletedPhase 1Boehringer IngelheimNCT03100916Written as BI 690517
Codes
What other systems call vicadrostat · ClinicalTrials.gg INT015998
- UNII (FDA) AF4VW4GA3HVICADROSTATConfirmed FDA, Wikidata
- Wikidata Q141129886vicadrostatConfirmed FDA, Wikidata
- NCI Thesaurus C207013VicadrostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AF4VW4GA3H | VICADROSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q141129886 | vicadrostat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C207013 | Vicadrostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.